Address

Pfizer Inc
235 East 42nd Street
150/39/18
New York, NY 10017
United States

Open map


Recent investment activity

KANDO id: 4229

Corporate information

Official name
Pfizer Incorporated
Registration country

Funding rounds

Top investment portfolio themes

Actual initial investment stage

Investment activity status
Active investor

Selected investments

Displaying 1 - 25 of 25
Profile Country Date Sort ascending Funding
Phoenix Venture Partners II LP Venture capital fund focused on advanced materials startups. Fund Closing Initial investment
Medivation Inc Acquisition USD 14,000,000,000 (USD 14,000,000,000)
Anacor Pharmaceuticals Inc Acquisition Initial investment led the round USD 5,200,000,000 (USD 5,200,000,000)
Icagen Inc Biopharmaceutical company developing small molecule therapeutics that target ion channels for treatment of a variety of diseases. Acquisition USD 56,000,000 (USD 56,000,000)
DVS Sciences Inc An analytical instrument and reagents company founded in Toronto Series A
Neuronetics Inc Series E
King Pharmaceuticals Acquisition Initial investment led the round USD 3,600,000,000 (USD 3,600,000,000)
FoldRx Pharmaceuticals Inc Acquisition
TetraLogic Pharmaceuticals A leader in the discovery and development of small molecule drugs called Smac mimetics for the treatment of cancers. Series C (USD 5,000,000)
Avid Radiopharmaceuticals Inc Series D
Wyeth Pharmaceuticals Acquisition Initial investment USD 68,000,000,000 (USD 68,000,000,000)
Serenex Inc Oncology-focused drug development company Acquisition
Avid Radiopharmaceuticals Inc Series C
BioRexis Pharmaceutical Corp Acquisition
Avid Radiopharmaceuticals Inc Series A
Vicuron Pharmaceuticals Inc Acquisition USD 1,900,000,000 (USD 1,900,000,000)
IDUN Pharmaceuticals Inc Acquisition
Excaliard Pharmaceuticals Inc N/A
Coley Pharmaceutical Group Inc N/A
Esperion Therapeutics Inc N/A
Five Prime Therapeutics Inc N/A
NeuroTherapeutics Pharma Inc N/A
Celladon Corp N/A
Five Prime Therapeutics Inc N/A
Ablexis LLC Biotechnology company dedicated to developing an innovative, next-generation platform for antibody drug discovery. N/A

Team

Employee Position Email
Barbara J Dalton
Vice President
Venture Capital
[email protected]

Past employees

Selected Products / Customers

Financials